Merck & Co., Inc. (MRK)
| Previous Close | 130.72 |
| Open | 130.13 |
| Bid | 131.46 x 900 |
| Ask | 131.49 x 800 |
| Day's Range | 130.13 - 131.73 |
| 52 Week Range | 99.14 - 133.10 |
| Volume | |
| Avg. Volume | 8,436,882 |
| Market Cap | 333.359B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 146.23 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (2.36%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
- Zacks
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
- Insider Monkey
20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
- Yahoo Finance Video
Merck raises 2024 guidance on cancer drug demand
Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the pharmaceutical giant to raise its 2024 outlook. The company's performance was driven by strong demand for its cancer drug Keytruda. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
